• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管活性肠肽可使分离出的人支气管、肺动脉和肺实质条带舒张。

Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma.

作者信息

Saga T, Said S I

出版信息

Trans Assoc Am Physicians. 1984;97:304-10.

PMID:6535346
Abstract

VIP, an endogenous neuropeptide normally present in lungs and other organs, relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma in vitro. Pretreatment of these tissues with indomethacin (1 micrograms/ml) markedly enhances the basal tone and the relaxant effect of VIP. The VIP-induced relaxation, especially of pulmonary artery, has a long duration. As a relaxant of human pulmonary arterial strip, VIP is approximately 200 times as potent as prostacyclin, on a molar basis. The results suggest a possible role for VIP as a modulator of airway and pulmonary vascular tone, and as a potential bronchodilator and pulmonary vasodilator in human subjects.

摘要

血管活性肠肽(VIP)是一种内源性神经肽,正常存在于肺和其他器官中,在体外可使分离的人支气管、肺动脉和肺实质条带舒张。用吲哚美辛(1微克/毫升)预处理这些组织可显著增强基础张力以及VIP的舒张作用。VIP诱导的舒张,尤其是对肺动脉的舒张,持续时间较长。作为人肺动脉条带的舒张剂,按摩尔计算,VIP的效力约为前列环素的200倍。这些结果表明,VIP可能作为气道和肺血管张力的调节剂,以及作为人类受试者潜在的支气管扩张剂和肺血管扩张剂发挥作用。

相似文献

1
Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma.血管活性肠肽可使分离出的人支气管、肺动脉和肺实质条带舒张。
Trans Assoc Am Physicians. 1984;97:304-10.
2
Involvement of endothelial NO in the dilator effect of VIP on rat isolated pulmonary artery.内皮型一氧化氮参与血管活性肠肽对大鼠离体肺动脉的舒张作用。
Regul Pept. 2007 Mar 1;139(1-3):102-8. doi: 10.1016/j.regpep.2006.10.012. Epub 2006 Dec 14.
3
Protease inhibitors potentiate smooth muscle relaxation induced by vasoactive intestinal peptide in isolated human bronchi.蛋白酶抑制剂可增强血管活性肠肽在离体人支气管中诱导的平滑肌舒张作用。
Am J Respir Cell Mol Biol. 1990 May;2(5):449-52. doi: 10.1165/ajrcmb/2.5.449.
4
Effects of alpha calcitonin gene-related peptide in human bronchial smooth muscle and pulmonary artery.α-降钙素基因相关肽对人支气管平滑肌和肺动脉的作用。
Regul Pept. 2004 May 15;118(3):127-34. doi: 10.1016/j.regpep.2003.11.006.
5
Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies.Ro 25 - 1553:一种新型长效血管活性肠肽激动剂。第一部分:体外和体内支气管扩张研究。
J Pharmacol Exp Ther. 1994 Sep;270(3):1282-8.
6
Relaxation of isolated guinea pig trachea, bronchi and pulmonary arteries produced by vasoactive intestinal peptide (VIP).血管活性肠肽(VIP)对豚鼠离体气管、支气管及肺动脉的舒张作用。
Eur J Pharmacol. 1984 Feb 17;98(2):279-84. doi: 10.1016/0014-2999(84)90602-2.
7
Relaxant effects of vasoactive intestinal peptide and bethanechol in cat intrapulmonary artery.血管活性肠肽和氨甲酰甲胆碱对猫肺内动脉的舒张作用。
Eur J Pharmacol. 1983 Sep 16;93(1-2):121-4. doi: 10.1016/0014-2999(83)90039-0.
8
Relaxant action of VIP on cat pulmonary artery: comparison with acetylcholine, isoproterenol, and PGE1.血管活性肠肽对猫肺动脉的舒张作用:与乙酰胆碱、异丙肾上腺素及前列腺素E1的比较
J Appl Physiol Respir Environ Exerc Physiol. 1983 Jun;54(6):1607-11. doi: 10.1152/jappl.1983.54.6.1607.
9
The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery.
Naunyn Schmiedebergs Arch Pharmacol. 2001 Oct;364(4):314-20. doi: 10.1007/s002100100458.
10
Vasoactive intestinal peptide as a possible transmitter of nonadrenergic, noncholinergic relaxation of pulmonary artery.
Trans Assoc Am Physicians. 1985;98:233-42.

引用本文的文献

1
Emerging biologics for the treatment of pulmonary arterial hypertension.新型生物制剂治疗肺动脉高压。
J Drug Target. 2023 Jun;31(5):1-15. doi: 10.1080/1061186X.2023.2199351. Epub 2023 Apr 26.
2
Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.靶向 VIP 和 PACAP 受体信号:设计 PACAP 受体亚家族药物的新见解。
Int J Mol Sci. 2022 Jul 22;23(15):8069. doi: 10.3390/ijms23158069.
3
NFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease.
特发性肺纤维化和慢性阻塞性肺疾病中的NFATc3与血管活性肠肽
PLoS One. 2017 Jan 26;12(1):e0170606. doi: 10.1371/journal.pone.0170606. eCollection 2017.
4
Gene Deletion of VIP Leads to Increased Mortality Associated with Progressive Right Ventricular Hypertrophy.血管活性肠肽基因缺失导致与进行性右心室肥厚相关的死亡率增加。
J Cardiovasc Dis. 2014 Apr 1;2(3):131-136.
5
Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.RO 25-1553 这种稳定的血管活性肠肽类似物对鼠肺和大鼠肺的血管舒张作用。
PLoS One. 2013 Sep 19;8(9):e75861. doi: 10.1371/journal.pone.0075861. eCollection 2013.
6
Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics.血管活性肠肽吸入激动剂:在呼吸治疗中的潜在作用。
Hippokratia. 2013 Jan;17(1):12-6.
7
VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.VIP 和内皮素受体拮抗剂:治疗实验性肺动脉高压的有效联合。
Respir Res. 2011 Oct 26;12(1):141. doi: 10.1186/1465-9921-12-141.
8
Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.COPD/PAH 和哮喘的血管活性肠肽治疗前景:综述。
Respir Res. 2011 Apr 11;12(1):45. doi: 10.1186/1465-9921-12-45.
9
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.血管活性肠肽作为治疗原发性肺动脉高压的新药。
J Clin Invest. 2003 May;111(9):1339-46. doi: 10.1172/JCI17500.
10
VIP antagonists enhance excitatory cholinergic neurotransmission in the human airway.血管活性肠肽拮抗剂可增强人气道中的兴奋性胆碱能神经传递。
Lung. 1994;172(3):159-67. doi: 10.1007/BF00175944.